{"id":24778,"date":"2026-02-18T10:41:00","date_gmt":"2026-02-18T09:41:00","guid":{"rendered":"https:\/\/vasro.de\/?p=24778"},"modified":"2026-02-26T02:46:31","modified_gmt":"2026-02-26T01:46:31","slug":"ainos-update-what-we-learn-from-the-veldona-fcgs-interim-readout","status":"publish","type":"post","link":"https:\/\/vasro.de\/en\/ainos-update-what-we-learn-from-the-veldona-fcgs-interim-readout\/","title":{"rendered":"Ainos Update \u2014 What We Learn from the VELDONA\u00ae FCGS Interim Readout"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">This update is a clinical signal calibration note. Ainos reported interim results from an ongoing <strong>open-label, multi-dose<\/strong> study of <strong>VELDONA\u00ae (low-dose oral interferon alpha)<\/strong> in <strong>Feline Chronic Gingivostomatitis (FCGS)<\/strong>. The interim cut covers <strong>6 treated cats<\/strong> out of <strong>12 planned<\/strong>, across two dose cohorts, dosed orally three times per week for six weeks, with follow-up reported through Week 14.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The point of this report is not to oversell early data. It is to translate company-reported outcomes into a disciplined \u201cwhat can we actually infer?\u201d framework. The update explains why this readout matters: it is the first quantified snapshot of how VELDONA is performing in FCGS, linking measured inflammation scoring to tolerability in a real-world veterinary setting\u2014useful as an evidence point, but not decisive because of the interim, open-label design and small sample size.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The report summarizes the company\u2019s primary disease activity framework (SDAI) and then focuses on the most concrete interim observations the company disclosed:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>On local oral inflammation, <strong>6\/6 cats<\/strong> showed lower scores at Week 6 versus baseline, with mean improvement reported at <strong>~38% at Week 6<\/strong> and <strong>~45% at Week 14<\/strong>, and a company-cited Wilcoxon signed-rank p &lt; 0.05.<\/li>\n\n\n\n<li>The dashboard view also highlights that <strong>66.7%<\/strong> achieved at least <strong>30% improvement<\/strong> (company-reported), and it flags the evidence level explicitly (interim; open-label; n=6\/12; dental procedures in 5\/6 subjects).<\/li>\n\n\n\n<li>On safety\/tolerability, the company reports stable routine labs through Week 6 and no dose-related toxicity trend in the interim set.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Crucially, the update puts this in the correct portfolio context for Ainos: in the initiating coverage, VASRO framed Ainos as <strong>two engines with two timelines<\/strong>, with AI Nose as the near-term execution focus and VELDONA as longer-dated optionality. Within that structure, FCGS sits as a secondary\/exploratory lane\u2014worth monitoring, but not the core commercialization driver.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/vasro.de\/wp-content\/uploads\/2026\/02\/VASRO-GmbH_Update-Report_Ainos-Inc_021826.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Access the Update 18 Feb 2026<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>This update is a clinical signal calibration note. Ainos reported interim results from an ongoing open-label, multi-dose study of VELDONA\u00ae (low-dose oral interferon alpha) in Feline Chronic Gingivostomatitis (FCGS). The interim cut covers 6 treated cats out of 12 planned, across two dose cohorts, dosed orally three times per week for six weeks, with follow-up&#8230;<\/p>\n","protected":false},"author":20,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1827],"tags":[],"class_list":["post-24778","post","type-post","status-publish","format-standard","hentry","category-equity-research-coverage"],"_links":{"self":[{"href":"https:\/\/vasro.de\/en\/wp-json\/wp\/v2\/posts\/24778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vasro.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vasro.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vasro.de\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/vasro.de\/en\/wp-json\/wp\/v2\/comments?post=24778"}],"version-history":[{"count":1,"href":"https:\/\/vasro.de\/en\/wp-json\/wp\/v2\/posts\/24778\/revisions"}],"predecessor-version":[{"id":24779,"href":"https:\/\/vasro.de\/en\/wp-json\/wp\/v2\/posts\/24778\/revisions\/24779"}],"wp:attachment":[{"href":"https:\/\/vasro.de\/en\/wp-json\/wp\/v2\/media?parent=24778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vasro.de\/en\/wp-json\/wp\/v2\/categories?post=24778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vasro.de\/en\/wp-json\/wp\/v2\/tags?post=24778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}